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Abstract
Background: Despite	its	known	insulin-independent	effects,	glucagon-like	peptide-1	
(GLP-1)	role	in	muscle	protein	turnover	has	not	been	explored	under	fed-state	condi-
tions	or	in	the	context	of	older	age,	when	declines	in	insulin	sensitivity	and	protein	
anabolism,	as	well	as	losses	of	muscle	mass	and	function,	occur.
Methods: Eight	older-aged	men	(71	±	1	year,	mean	± SEM)	were	studied	in	a	crosso-
ver	trial.	Baseline	measures	were	taken	over	3	hr,	prior	to	a	3	hr	postprandial	insulin	
(~30 mIU ml−1)	and	glucose	(7–7.5	mM)	clamp,	alongside	I.V.	infusions	of	octreotide	
and	Vamin	14	 (±infusions	of	GLP-1).	Four	muscle	biopsies	were	taken,	and	muscle	
protein	 turnover	was	quantified	 via	 incorporation	of	 13C6 phenylalanine and arte-
riovenous	balance	kinetics,	using	mass	spectrometry.	Leg	macro-	and	microvascular	
flow	was	assessed	via	ultrasound	and	anabolic	signalling	by	immunoblotting.	GLP-1	
and	insulin	were	measured	by	ELISA.
Results: GLP-1	augmented	muscle	protein	synthesis	(MPS;	fasted:	0.058	± 0.004% hr−1 
vs. postprandial: 0.102 ± 0.005% hr−1,	p <	0.01),	in	comparison	with	non-GLP-1	tri-
als.	Muscle	protein	breakdown	(MPB)	was	reduced	throughout	clamp	period,	while	
net protein balance across the leg became positive in both groups. Total femoral leg 
blood	flow	was	unchanged	by	the	clamp;	however,	muscle	microvascular	blood	flow	
(MBF)	was	significantly	elevated	in	both	groups,	and	to	a	significantly	greater	extent	
in	the	GLP-1	group	(MBF:	5	± 2 vs. 1.9 ± 1 fold change +GLP-1	and	−GLP-1,	respec-
tively,	p <	0.01).	Activation	of	the	Akt-mTOR	signalling	was	similar	across	both	trials.
Conclusion: GLP-1	infusion	markedly	enhanced	postprandial	microvascular	perfusion	
and	further	stimulated	muscle	protein	metabolism,	primarily	through	increased	MPS,	
during a postprandial insulin hyperaminoacidaemic clamp.
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1  | INTRODUC TION
Increases	in	muscle	protein	synthesis	(MPS)	and	decreases	in	breakdown	
(MPB)	after	feeding,	which	recoup	muscle	protein	losses	during	fasting,	
are crucial for muscle maintenance. The primary driver of increased 
MPS	are	dietary	essential	 amino	acids	 (EAAs)	 (Atherton	et	 al.,	 2010;	
Cuthbertson	et	al.,	2005),	which	 induce	a	marked	 (~2-	 to	3-fold),	but	
transient (~2-3	hr)	elevation	in	MPS,	even	in	the	presence	of	continued	
EAA	availability	 (Atherton	et	 al.,	 2010).	Conversely,	 insulin	promotes	
muscle	protein	anabolism,	primarily	via	suppression	of	MPB	(Abdulla,	
Smith,	Atherton,	&	Idris,	2016;	Cuthbertson	et	al.,	2005),	concomitantly	
enhancing	microvascular	recruitment,	 increasing	substrate	delivery	to	
muscle	(Barrett,	Wang,	Upchurch,	&	Liu,	2011)	and	promoting	the	up-
take	and	storage	of	glucose	in	muscle	cells	(Timmerman	et	al.,	2010).
In	 ageing,	 skeletal	 muscle	 becomes	 resistant	 to	 the	 anabolic	
effects	 of	 dietary	 EAA	 and	 insulin—termed	 ‘anabolic	 resistance’	
(Cuthbertson	 et	 al.,	 2005;	Moore	 et	 al.,	 2015;	Wall	 et	 al.,	 2015).	
This	manifests	as	an	inability	of	muscle	to	sequester	EAA	during	the	
postprandial	state	 (Cuthbertson	et	al.,	2005;	Katsanos,	Kobayashi,	
Sheffield-Moore,	Aarsland,	&	Wolfe,	2005),	while	the	anti-catabolic	
effect	of	insulin	in	reducing	MPB	is	also	impaired	(Wilkes	et	al.,	2009)	
(as	is	the	inhibition	of	whole-body	protein	breakdown;	Guillet	et	al.,	
2004)—ostensibly	leading	to	net	losses	of	muscle	protein	over	time	
(Cuthbertson	et	al.,	2005;	Moore	et	al.,	2015).	 In	addition,	glucose	
uptake	and	storage	in	muscle	are	also	reduced,	as	a	result	of	impaired	
insulin	signalling	(Castellino,	Luzi,	Simonson,	Haymond,	&	DeFronzo,	
1987;	 Churchward-Venne	 et	 al.,	 2012;	 Cuthbertson	 et	 al.,	 2005;	
Hamer	et	al.,	2013;	Moore	et	al.,	2015;	Wilkes	et	al.,	2009).	Further,	
there	is	a	loss	of	vascular	function	and	nutrient-induced	blood	flow	
with	age	(Keske	et	al.,	2016),	which	may	contribute	further	to	dysreg-
ulated	 substrate	 delivery	 and	 impaired	 glycaemic	 control	 (Barzilay	
et	al.,	2009;	Fujita,	Glynn,	Timmerman,	Rasmussen,	&	Volpi,	2009).
A	major	hormonal	 response	 to	nutrition	 (in	addition	 to	 insulin)	
is	 the	 release	 of	 gut-derived	 hormones.	 In	 particular,	 the	 incretin	
hormone,	glucagon-like	peptide	(GLP-1),	has	emerged	as	a	key	reg-
ulator	of	postprandial	glucose	metabolism	through	its	ubiquitously	
expressed	receptor	(GLP-1r)	(Delgado	et	al.,	1995).	GLP-1	is	released	
from	 the	 neuroendocrine	 L	 cells	 of	 the	 gut	 in	 response	 to	 intake	
of	macro-nutrients	(Elliott	et	al.,	1993),	limiting	postprandial	hyper-
glycaemia via enhancing β-cell	 insulin	secretion,	suppressing	α-cell	
glucagon	and	delaying	gastric	emptying	(Holst,	Vilsbøll,	&	Deacon,	
2009;	 Kreymann,	Williams,	 Ghatei,	 &	 Bloom,	 1987;	Willms	 et	 al.,	
1996).	Previous	data	also	demonstrate	that	GLP-1	stimulates	muscle	
glucose	uptake	(Idris,	Patiag,	Gray,	&	Donnelly,	2002),	likely	through	
enhancing	skeletal	muscle	microvascular	blood	flow	(MBF)	in	an	in-
sulin-independent	manner	(Subaran	et	al.,	2014).
Crucially,	recent	data	have	emerged	suggesting	a	novel	role	of	
GLP-1	 in	 relation	 to	muscle	 protein	metabolism	 and	muscle	mass	
regulation.	 For	 example,	 longer-term	 observational	 studies	 with	
inhibitors	of	 the	GLP-1-degrading	enzyme,	dipeptidyl	peptidase-4	
(DPP-4),	demonstrate	improved	muscle	mass	preservation	in	older	
age	 (Bouchi	 et	 al.,	 2018).	 Moreover,	 recently	 a	 comprehensive	
pre-clinical	study	demonstrated	that	exendin-4—a	peptide	agonist	
of	GLP-1r—suppressed	the	expression	of	molecules	involved	in	mus-
cle	atrophy,	for	example	atrogin	1	and	MURF-1,	and	preserved	mus-
cle	in	mouse	models	of	muscle	wasting	(Hong,	Lee,	Jeong,	Choi,	&	
Jun,	2019).	However,	evidence	of	a	direct	effect	of	GLP-1	on	human	
muscle protein metabolism is lacking and its potential impact on 
‘anabolic	resistance’	in	ageing	muscle	is	unexplored.	Therefore,	the	
aims	 of	 this	 study	were	 to	 determine	 the	 acute	 impact	 of	 GLP-1	
in	relation	to	muscle	protein	metabolism.	We	hypothesised	GLP-1	
would promote greater protein anabolism in older muscle in re-
sponse to amino acid feeding during a postprandial insulin clamp.
2  | RESULTS
2.1 | Subject characteristics
The physical and demographic characteristics of study participants 
are described in Table 1.
2.2 | GLP-1 and Insulin concentrations
GLP-1	 levels	 at	baseline	 in	 the	 two	were	 similar;	however,	upon	 in-
fusion	of	GLP-1,	 levels	 rose	 rapidly	peaking	 around	40	min,	 but	 re-
mained	 unchanged	 throughout,	 in	 the	 control	 group.	 Mean	 GLP-1	
concentration over the postprandial period was 63 ±	15	pmol	L−1 and 
17 ±	4	pmol	L−1	with	and	without	GLP-1	 infusion,	 respectively,	 and	
the	AUC	above	baseline	was	significantly	greater	in	the	GLP-1	group	
(Figure	1a)	(inset).	Postabsorptive	insulin	concentrations	were	similar	
K E Y W O R D S
glucagon-like	peptide	1,	microvascular	blood	flow,	muscle	protein	breakdown,	muscle	protein	
synthesis
TA B L E  1   Characteristics of study participants
Parameter Participants (n = 8)
Age	(year) 71 ± 1
Height	(m) 1.77 ± 0.03
Weight	(kg) 83	± 4
BMI	(kg	m−2) 26.2 ± 0.6
Leg	muscle	mass	(g) 9201 ±	28
Sarcopenic	index	(kg	m−2) 8.13	±	0.18
Fasting	plasma	glucose	(mM	L−1) 5.6 ± 0.2
Ethnicity Caucasian:	7	(87.5%)
South	Asian:	1	(12.5%)
Note: Data are presented as mean ± SEM.
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at baseline in both groups (5.1 ± 0.5 and 5.6 ± 0.9 μIU ml−1 with and 
without	GLP-1,	respectively).	During	the	postprandial	clamp	with	insu-
lin	alone,	levels	rose	to	25	± 0.4 μIU ml−1 and to 31 ± 1.3 μIU ml−1 when 
GLP-1	was	co-infused	(p <	0.001	vs.	fasting	for	both)	(Figure	1b);	AUC	
above	baseline	is	shown	in	the	inset,	for	−GLP-1	and	+GLP-1,	p = 0.24.
2.3 | Phenylalanine concentration and enrichment
Arterial	phenylalanine	concentrations	were	similar	at	baseline	in	both	
groups	(58.5	± 2.7 μM	−GLP-1	vs.	60.8	± 3.4 μM +GLP-1	and	rose	
significantly over the first 90 min of the postprandial period in both 
groups	more	than	doubling	to	135.8	±	6.8	μM and 130.5 ± 2.7 μM,	
respectively,	 both	p <	 0.0001	Figure	2a,b)	 and	 remained	elevated	
throughout. Phenylalanine concentrations were used as a proxy to 
illustrate	the	effect	of	Vamin	infusion	on	circulating	AA	concentra-
tions,	mimicking	a	feeding	response.
Phenylalanine enrichment reached a steady state rapidly during 
the baseline period and then fell similarly in both groups to a new 
steady	state	during	the	postprandial	clamp	(Figure	2c,d),	due	to	the	
presence	 of	 unlabelled	 Phe	 in	 the	 Vamin	 infusion.	 Phenylalanine	
kinetics	 were	 determined	 over	 three	 periods	 as	 outlined	 below,	
when leg blood flow was simultaneously measured (see protocol 
Figure	3).
2.4 | Total leg blood flow and microvascular 
blood flow
Although	 total	 leg	 blood	 flow	 rose	 slightly,	 during	 the	 postpran-
dial	clamp	in	both	groups,	this	was	not	significant	 (0.34	± 0.02 vs. 
0.39 ±	0.03	L	min−1	−GLP-1,	and	0.33	± 0.02 vs. 0.37 ±	0.031	L	min−1,	
+GLP-1,	Figure	4a,b).	With	regard	to	microvascular	recruitment,	re-
plenishment	 curves	 of	 AI	 at	 baseline	 and	 during	 the	 postprandial	
clamp,	with	and	without	GLP-1,	are	shown	in	Figure	4c,d,	showing	
the impact of the postprandial clamp on tissue perfusion. In re-
sponse	to	the	clamp	without	GLP-1,	MBF	increased	from	0.14	± 0.04 
to 0.25 ± 0.05 ml s−1	 (baseline	 vs.	 postprandial	 clamp,	 p <	 0.05,	
Figure	 4e),	 whereas	 co-infusion	 of	 GLP-1	 increased	 MBF	 from	
0.06 ± 0.01 to 0.22 ± 0.07 ml s−1	(baseline	vs.	postprandial	clamp,	
p <	0.01,	Figure	4f),	representing	a	fold	of	change	from	baseline	of	
5 ± 2.1 (+GLP-1)	versus	1.9	±	0.7	(−GLP-1),	p <	0.01,	Figure	4g.
2.5 | Myofibrillar Protein Synthesis (MPS)
MPS	 was	 similar	 in	 both	 experiments	 under	 postabsorptive	 con-
ditions	 (0.058	±	0.008%	hr−1 vs. 0.063 ± 0.003% hr−1,	−GLP-1	vs.	
+GLP-1,	 respectively,	 Figure	 5).	 During	 the	 postprandial	 clamp,	
MPS	 rose	 slightly,	 but	 non-significantly	 in	 the	 −GLP-1	 group	
F I G U R E  1  GLP-1	concentration	
over	180	min	postprandial	clamp	(a)	
and	AUC	above	baseline	(inset).	Insulin	
concentrations at fasted and following 
fed-state	clamp	with	and	without	GLP-1	
(b)	and	insulin	AUC	above	baseline	(inset).	
**p <	0.01	versus	respective	fasted	value,	
§p <	0.05	versus	–	GLP-1	respective	time	
point,	§§p <	0.01	versus	–GLP-1	respective	
time	point,	****p < 0.0001 versus 
respective fasted values. ap < 0.01 versus 
–	GLP-1.	Data	reported	as	mean	± SEM
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(0.075 ±	0.008%	hr−1,	p =	0.23);	however,	co-infusion	of	GLP-1	re-
sulted	 in	 a	 significantly	 greater	 rise	 in	MPS	 (0.102	± 0.005% hr−1,	
p <	0.01,	also	p <	0.05	compared	to	MPS	of	−GLP-1	in	postprandial	
phase).
2.6 | Phenylalanine leg turnover kinetics
Phenylalanine kinetics across the leg are summarised in 
Figure 6. Phenylalanine delivery to the leg at baseline was not dif-
ferent in both groups and increased during the postprandial clamp 
(272 ± 23 vs. 752 ±	48	nmol	100	g	leg−1 min−1,	and	244	± 20 vs. 
690 ± 45 nmol 100 g leg−1 min−1,	both	p <	0.001,	with	and	without	
GLP-1,	respectively).
The	rate	of	appearance,	Ra,	of	phenylalanine	was	similar	in	both	
groups at baseline (46 ± 2 nmol 100 g leg−1 min−1,	 −GLP-1,	 and	
54 ± 2 nmol 100 g leg−1 min−1,	+GLP-1)	 during	 the	 postprandial	
clamp	Ra	fell	similarly,	at	0–90	min	and	90–180	min	in	both	−GLP-
1,	 (to	26	± 2 and 10 ± 6 nmol 100 g leg−1 min−1,	−43%,	p < 0.005 
and	−78%,	p <	0.001,	respectively)	and	+GLP-1	groups,	 (to	31	± 4 
and 20 ± 5 nmol 100 g leg−1 min−1,	−43%	days,	p <	0.01	and	−63%,	
p <	0.001,	respectively;	Figure	6a).
Muscle	 protein	 net	 balance	 (NB)	 was	 negative	 in	 both	
groups	 in	 the	 fasted	 state	 (−10.0	±	 3	 vs.	 −13.6	± 3 nmol 100 g 
leg−1 min−1,	 −GLP-1	 and	 +GLP-1,	 respectively).	 NB	 became	 sig-
nificantly more positive during postprandial clamp at both 
0–90	and	90–180	min	 (−GLP-1,	26.1	± 9 nmol 100 g leg−1 min−1,	
p < 0.001 and 12.2 ± 7 nmol 100 g leg−1 min−1,	p < 0.05. +GLP-1	
39.0 ± 3 nmol 100 g leg−1 min−1,	p < 0.001 and 14.2 ±	8	nmol	100	g	
leg−1 min−1,	p <	0.01).	The	difference	between	the	two	groups	 (−
GLP-1	 vs.	+GLP-1)	was	 not	 significant	 at	 both	 stages	 of	 feeding	
(Figure	6b).
The	 rate	 of	 disappearance	 (Rd),	 that	 is	 synthesis,	 was	 not	
different between the two in the fasted state (36.4 ± 3 vs. 
40.6 ± 6 nmol 100 g leg−1 min−1).	 The	 Rd	 rose	 slightly,	 but	
not	 significantly,	 in	 the	 postprandial	 state	 without	 GLP-1	
(52.3 ± 10 nmol 100 g leg−1 min−1);	 however,	 during	 GLP-1	 in-
fusion,	 Rd	 was	 significantly	 elevated	 during	 the	 0-90	 min	
(70.3 ± 5 nmol 100 g leg−1 min−1,	p <	 0.05),	 before	 returning	 to	
fasted	levels	at	90–180	min	in	both	groups	(Figure	6c).
F I G U R E  2  Phenylalanine	concentrations	(A&B)	and	enrichment	(C&D)	at	baseline	(fasted	state)	and	following	postprandial	clamp	(fed	
state),	with	and	without	GLP-1.	Steady-state	enrichment	(A&B)	and	concentrations	in	fasted	and	fed	state	(C&D)	in	the	femoral	artery	and	
vein	with	and	without	GLP-1.	***p <	0.001	versus	baseline,	****p < 0.0001 versus baseline
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2.7 | Anabolic signalling
Phosphorylation	of	both	AKT	Ser473	 and	p70	S6K	Thr389 rose sig-
nificantly	in	response	to	the	insulin	and	AA	clamp	(2.5-	and	5.7-fold	
increment	from	fasted,	 respectively),	with	no	additional	effect	ob-
served	with	GLP-1	infusion	(3.1-	and	5.3-fold	increment	from	fasted,	
respectively)	(Figure	S1:	B	and	E).	Neither	mTOR	Ser2448,	eEF2	Thr56,	
4E-BP1	 Thr37/46	 nor	 TSC2	 Thr1462 activities were affected by the 
postprandial	clamp	(Figure	S1:	A,	C,	D	and	F).
2.8 | Gene expression of GLP1r
Our data show sufficient expression of the receptor in both skeletal 
muscle	cells	and	skeletal	muscle	tissue.	Data	in	Figure	S2	show	gene	
expression of GLP1r in different human tissue/cell types expressed 
as	fold	difference	in	relation	to	the	housekeeping	gene	(RPL13A).
3  | DISCUSSION
In	the	present	study,	we	demonstrate	an	anabolic	effect	of	GLP-1	in	
skeletal	muscle	of	older	humans	under	fed-state	conditions.	In	line	
with	previous	findings	in	older	individuals,	MPS	was	resistant	to	the	
impact	of	intravenous	AA	feeding	under	postprandial	insulin	condi-
tions	 (in	the	absence	of	GLP-1)	 (Cuthbertson	et	al.,	2005;	Mitchell	
et	 al.,	 2017).	 In	 contrast,	GLP-1	 infusions	 adjuvant	 to	 the	 intrave-
nous	AA/insulin	infusions	resulted	in	a	significant	augmentation	of	
MPS	over	−GLP-1	conditions,	as	 such	 rescuing	anabolic	 responses	
to	AA	feeding.	Finally,	a	sustained	suppression	of	MPB	during	insu-
lin	clamps	was	observed	throughout	the	postprandial	insulin	clamp,	
and	to	the	same	extent	in	both	groups,	indicating	that	GLP-1	had	no	
added	effect	upon	the	inhibition	of	MPB.
Impaired anabolic responses to nutrition are a hallmark of age-
ing	muscle	 (Cuthbertson	et	al.,	2005;	Wall	et	al.,	2015).	Here,	we	
demonstrate for the first time through both direct incorporation 
and	A-V	balance	methods	 that	GLP-1	 infusion	under	postprandial	
insulin,	 hyperaminoacidaemic	 clamp	 conditions,	 further	 enhanced	
fed-state	MPS	rates	 in	humans,	possibly	 indicating	a	direct	effect	
of	GLP-1	at	a	cellular	level	in	muscle.	We	also	detected	GLP-1r	ex-
pression	in	muscle;	in	line	with	this,	other	workers	have	shown	that	
GLP-1r	 agonists	 can	 induce	 protein	 kinase	 B	 (Akt),	 mitogen-acti-
vated	protein	kinases	and	p70	ribosomal	S6	kinase	(p70S6K)	signal-
ling	in	skeletal	muscle	cells	(González,	Acitores,	Sancho,	Valverde,	&	
Villanueva-Peñacarrillo,	2005;	Villanueva-Peñacarrillo	et	al.,	2011).	
Since	these	pathways	are	 involved	 in	anabolic	responses	to	nutri-
tion	driven	by	AA	(Fujita	et	al.,	2007)	and	insulin	(Hillier,	Long,	Jahn,	
Wei,	 &	 Barrett,	 2000),	we	 investigated	 the	 activation	 of	 key	 sig-
nalling	molecules	in	the	absence	and	presence	of	GLP-1.	However,	
despite	enhanced	postprandial	MPS	with	GLP-1	 infusions,	and	 in-
creased	phosphorylation	of,	for	example,	AKT	Ser473	and	p70	S6K	
Thr389	during	the	clamps,	there	were	no	additional	differences	ap-
parent	with	GLP-1	that	could	explain	the	elevated	MPS.	Similarly,	
mTOR	Ser2448,	eEF2	Thr56,	4E-BP1	Thr37/46	and	TSC2	Thr1462 were 
unaffected by the postprandial clamp and were not different be-
tween the groups. These findings further highlight the temporal 
and	quantitative	disconnect	between	 the	activity	of	 anabolic	 sig-
nalling	and	 the	quantitative	stimulation	of	MPS,	 in	humans	under	
fed-state	 conditions	 (Greenhaff	 et	 al.,	 2008),	 and	 further	work	 is	
needed	to	define	these	limitations.	On	long-term	provision	of	ther-
apeutic	 GLP-1r	 agonists,	 mainly	 to	 achieve	weight	 loss	 and	 opti-
mise	glucose	control,	the	resultant	weight	loss	was	predominantly	
F I G U R E  3  Schematic	representation	
of	study	protocol.	8	older	men	studied	in	a	
crossover design in the fasted +	fed	state,	
with	and	without	GLP-1.	CEUS,	contrast-
enhanced	ultrasound;	LBF,	leg	blood	flow
0 1 2 3 4 5 6
Postprandial Insulin clamp ± GLP-1 (1.2
pmol.kg–1.min–1)
Octreode 30 ng.kg–1.min–1
IV Vamin 14-EF providing ≤20 g mixed
AA
IV 20% Glucose; 7-7.5 mM.L–1 Glucose clamp
8 Older
Men
CEUS
Muscle
biopsies
Arterial blood
samples
Venous blood
samples
13C6 Phenylalanine (0.4 mg.kg–1 Prime; 0.6 mg.kg–1. h–1 constant infusion)
LBF
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fat mass and to a lesser extent some lean body mass loss has been 
reported	(Sargeant	et	al.,	2019).	Nonetheless,	acutely,	GLP-1	infu-
sions have clear translational potential in muscle mass attainment in 
settings where intentional weight loss is not the primary outcome 
being sought.
In	order	to	seek	other	mechanisms	relating	to	GLP-1's	effects,	
we	 also	 quantified	muscle	 perfusion.	 Age-related	 attenuation	 of	
vascular	 responses	 to	 feeding	 is	 well	 documented,	 and	we	 have	
previously	described	the	existence	of	fed-state	microvascular	re-
sistance	 in	 older	 age	 and	 its	 co-existence	 with	 impaired	 muscle	
anabolic	 response	 (Phillips	 et	 al.,	 2014).	We	 demonstrate	 in	 the	
present	study	a	greater	increase	in	muscle	MBF	in	response	to	feed-
ing	 alongside	 GLP-1	 infusion	 (vs.	 −GLP-1).	 Although	 some	 argue	
that increased tissue perfusion is a driver of enhanced protein 
anabolism,	for	example	increases	in	MPS	(Timmerman	et	al.,	2010),	
our previous studies investigating the impact of altering blood flow 
pharmacologically	 (Phillips	et	al.,	2014)	and	muscle	microvascular	
perfusion	 following	 resistance	 exercise	 training	 (Phillips	 et	 al.,	
2012)	 demonstrated	no	 additional	 anabolic	 effects	 in	 relation	 to	
muscle	protein	turnover.	Notably,	in	our	study,	GLP-1	was	infused	
F I G U R E  4   Microvascular responses to postprandial insulin ±	GLP-1	measured	by	CEUS.	LBF	measured	by	Doppler	ultrasound	at	baseline	
and	during	the	postprandial	clamp	with	and	without	GLP-1	is	shown	in	b	and	a,	respectively.	Graphs	c	and	d	show	acoustic	intensity	(AI)	
generated	from	microvascular	microbubble	contrast	refilling	(corresponding	to	MBV)	plotted	against	time.	MBF	at	baseline	and	following	
feeding	alone	and	with	GLP-1	is	shown	in	e	and	f,	respectively.	Fold	change	in	MBF	from	baseline	following	feeding	with	and	without	GLP-1	
is shown in g. *p <	0.05,	**p <	0.01.	AI,	acoustic	intensity;	MBF,	microvascular	blood	flow;	MBV,	microvascular	blood	volume;	LBF,	leg	blood	
flow. Data presented as mean ± SEM
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intra-arterially	in	contrast	to	studies	in	rats	(Chai	et	al.,	2012)	and	
humans	(Sjøberg,	Holst,	Rattigan,	Richter,	&	Kiens,	2014;	Subaran	
et	 al.,	 2014),	 where	 GLP-1	was	 infused	 intravenously.	 Given	 the	
short	half-life	of	GLP-1,	 the	marked	effects	we	observe	on	MBF	
were	possibly	due	to	the	direct	vasodilatory	properties	of	GLP-1.	
Finally,	 enhanced	MBF	may	 instead	 play	 a	 crucial	 role	 in	muscle	
glucose	uptake	(Vincent	et	al.,	2004).
Recently,	chronic	provision	of	antiglycaemic	DPP-4	inhibitors	
was	 shown	 to	 result	 in	 increases	 in	muscle	mass	 (Bouchi	 et	 al.,	
2018),	although	the	mechanistic	basis	for	the	observed	benefits	
was	not	studied.	Similarly,	recent	work	in	mice	has	shown	the	po-
tential	 of	 GLP-1	 agonism	 in	 relation	 to	 skeletal	 muscle	 mainte-
nance	 in	 catabolic	disease	models	 (Hong	et	 al.,	 2019).	Our	data	
indicate	 that	 GLP-1	 infusion	 restores	 the	 anabolic	 response	 to	
EAA	 provision	 in	 older	 muscle,	 which	may	 help	 explain	 the	 in-
crease or maintenance in muscle mass observed in these previous 
studies.	In	the	context	of	diabetes,	GLP-1	therapy	is	widely	used	
in	clinical	practice,	 to	 improve	glucose	uptake	and	disposal,	and	
given that muscle loss and the incidence of sarcopenia is acceler-
ated	in	patients	with	diabetes	(Park	et	al.,	2007),	GLP-1	therapies	
may also have a role to play in maintaining muscle mass.
Our study is limited by the nature of its short duration in demon-
strating	these	metabolic	and	microvascular	gains.	As	we	have	previ-
ously	reported	significant	sexual	dimorphism	in	MPS	in	response	to	
mixed	meal	ingestion	on	older	men	and	women	(Smith	et	al.,	2008),	
we	studied	only	older	men,	an	established	model	of	anabolic	resis-
tance,	to	ensure	minimal	confounding	factors	(i.e.	mixed	sex)	in	test-
ing	 the	effect	of	GLP-1	 infusion	on	older	human	muscle	 fed-state	
MPS.	Therefore,	our	findings	would	need	to	be	confirmed	in	older	
women and indeed in other populations with metabolic disease. 
Nonetheless,	for	the	first	time	in	ageing	human	muscle,	we	are	able	
to	demonstrate	 that	GLP-1	 infusions	 could	overcome	anabolic	 re-
sistance	to	feeding	and	enhance	muscle	MBF.	Following	these	find-
ings,	 further	mechanistic	 studies	and	clinical	 trials	are	 required	 to	
elucidate	the	impact	of	the	broad	array	of	GLP-1	therapies	available	
(agonists/DDP-4	inhibitors,	etc.)	in	relation	to	muscle	maintenance.
4  | MATERIAL S AND METHODS
4.1 | Subjects and design
The study was approved by The University of Nottingham Ethics 
Committee	 (Reference	Number:	G12122013	MSGEM)	and	was	con-
ducted	 in	 line	with	 the	Declaration	 of	Helsinki,	 2013.	 Eight	 healthy	
male	volunteers	(65–75	years	of	age,	see	Table	1	for	subject	character-
istics)	from	the	local	area	were	recruited	into	the	study,	via	mailshot.	
A	comprehensive	clinical	examination	and	metabolic	screening	were	
conducted	at	the	Royal	Derby	Medical	School,	Derby.	Subjects	with	
metabolic	 disease,	 lower	 limb	 musculoskeletal	 abnormalities,	 acute	
cerebrovascular	or	cardiovascular	disease,	active	malignancy,	uncon-
trolled	hypertension,	and	BMI	<18	or	>28	kg	m2,	on	medications	that	
impact muscle protein metabolism or modulate vascular tone or have 
known	allergy	to	any	of	the	study	drugs,	were	excluded.	All	volunteers	
were	studied	following	overnight	fasting	of	10–14	hr.	Each	volunteer	
was	studied	on	two	occasions,	at	least	3	weeks	apart.	Volunteers	were	
randomly	assigned	to	receive	either	glucagon-like	peptide-1	(GLP-1)	in-
fusion into the femoral artery in one leg or placebo in the contralateral 
leg.	Volunteers	were	blinded	to	which	visit	they	would	receive	GLP-1.
4.2 | Conduct of the study
4.2.1 | Reporting and initial preparation
On	 the	 morning	 of	 the	 study,	 volunteers	 reported	 to	 the	 Clinical	
Physiology	Laboratory	at	0800.	Following	a	DXA	scan,	volunteers	lay	
supine	on	a	bed.	Three	polyethylene	cannulae	(20G	×	2	&	18G	×	1)	
for	intravenous	infusions	were	inserted,	distributed	between	the	two	
forearms. This was followed by the insertion of femoral venous and 
arterial cannulae into the femoral artery and vein of the leg designated 
for study. The area below the inguinal ligament was anaesthetised be-
fore	 introduction	of	wire-guided	femoral	catheters	using	ultrasound	
scan	guidance	(Philips	iU22	Ultrasound,	Bothell,	WA,	USA).
4.2.2 | Labelled AA infusion
At	time	zero	after	baseline	venous	and	arterial	blood	sampling,	an	in-
fusion	 of	 L-[ring-13C6]-phenylalanine	 (Cambridge	 Laboratories,	 MA,	
USA)	was	started	(prime	0.4	mg	kg−1. then infused at 0.6 mg kg−1 hr−1)	
and	was	continued	until	the	end	of	the	study	(a	total	of	6	hr,	see	study	
protocol	for	timings).
4.2.3 | Muscle biopsies
Baseline	 muscle	 biopsies	 were	 taken	 at	 60	 min	 (after	 attainment	 of	
steady-state	isotope	labelling)	and	180	min	following	initiation	of	infusion	
and immediately before start of postprandial clamp. Two further muscle 
biopsies	were	taken	at	90	min	and	180	min	postinitiation	of	the	clamp.
F I G U R E  5   Fasted versus fed myofibrillar muscle protein 
synthesis	under	postprandial	clamp	conditions,	with	and	without	
GLP-1.	**p <	0.01	versus	respective	fasted,	§p < 0.05 versus 
fed	−GLP-1.	FSR,	fractional	synthesis	rate.	Data	reported	as	
means ± SEM
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4.2.4 | Postprandial clamp
Immediately	following	the	second	baseline	muscle	biopsy,	peripheral	in-
travenous	infusions	of	octreotide	(Novartis,	Surry,	UK),	 insulin	Actrapid	
(Novo	Nordisk,	Gatwick,	UK),	20%	glucose	(Baxter,	UK)	and	mixed	AA-
Vamin	14-EF	(Fresenius	Kabi	Ltd,	Runcorn,	UK)	±	femoral	arterial	GLP-1	
infusion	(Bachem	AG,	Bubendorf,	Switzerland)	were	started.	Octreotide	
was infused at a rate of 30 ng kg−1 min−1	(Greenhaff	et	al.,	2008).	Glucose	
and	 insulin	were	 infused	 as	 previously	 described	 (DeFronzo,	 Tobin,	 &	
Andres,	1979)	aiming	to	clamp	glucose	at	7–7.5	mM	L−1 and insulin at 
modest postprandial levels of around 30 μIU ml−1.	 Vamin	 14-EF	was	
started at a prime rate of 34 mg kg−1 followed by a constant infusion rate 
of 102 mg kg−1 hr−1	for	3	hr.	GLP-1	was	obtained	as	a	powder	and	stored	
at	−20°C.	On	the	day	of	the	study,	it	was	dissolved	in	2	ml	of	sterile	0.9%	
saline,	diluted	and	infused	into	the	femoral	artery	at	a	constant	rate	of	
1.2 pmol kg−1 min−1	(Subaran	et	al.,	2014).
4.2.5 | Contrast-enhanced ultrasound
At	145	min	 following	 the	start	of	 labelled	AA	 infusion,	baseline	meas-
urement	of	microvascular	parameters	was	conducted	using	contrast-en-
hanced	ultrasound	(CEUS—Philips	iU22	Ultrasound,	Bothell,	WA,	USA).	
SonovueTM	(Bracco,	Courcouronnes,	France)	was	infused	via	a	peripheral	
vein at an initial rate of 2 ml min−1 for 1 min and 1 ml min−1 for a further 
2	min.	During	the	three-min	duration,	three	cycles	of	flash/replenishment	
videos were recorded. Further assessment of microvascular parameters 
was made at 120 min following the start of the postprandial clamp.
4.2.6 | Blood sampling and leg blood flow
Regular venous and arterial blood samples were taken throughout. 
During	the	first	120–180	min,	three	sets	of	leg	femoral	artery	blood	
flow	 (LBF)	were	 taken.	This	 continued	 during	 the	 3-hr	 postprandial	
clamp	period;	regular	arterial	and	venous	samples	were	taken,	in	ad-
dition	to	regular	assessment	of	LBF	(see	protocol,	Figure	3).	Regular	
femoral	venous	samples	were	taken	every	5–10	min	during	the	3-hr	
postprandial period to help titrate glucose infusion to ensure blood 
glucose	stays	at	postprandial	levels	of	7–7.5	mmol	L−1.
At	the	end	of	 the	study,	participants	were	monitored	and	fed	
before	being	 allowed	 to	 leave.	Volunteers	 returned	 after	 at	 least	
3 weeks for the crossover study on the contralateral leg.
4.3 | Anthropometric indices
Body	mass	 index	 (BMI)	was	defined	as	weight	 in	kg	height	 in	m−2. 
Sarcopenic	 index	corresponds	 to	 the	appendicular	 skeletal	muscle	
mass	 index	 (ASMI),	which	was	 calculated	 as	 appendicular	 skeletal	
muscle	(ASM)	in	kg	height	in	m−2.
4.4 | Laboratory analysis and measurements
4.4.1 | Plasma insulin and GLP-1 concentrations
Commercial	ELISA	kits	(Milliplex	Map	kit,	EMS	Millipore,	Germany)	
were	used	 to	determine	 insulin,	C	peptide	and	GLP-1	concentra-
tions.	For	GLP-1,	blood	was	collected	 in	P800	 tubes,	 to	 stabilise	
F I G U R E  6   Phenylalanine kinetics across the leg in response to 
postprandial	insulin	with	and	without	GLP-1	in	a:	MPB,	b:	protein	
NB	and	c:	MPS.	PP	INS,	postprandial	insulin;	MPB,	muscle	protein	
breakdown;	NB,	net	balance.	*p <	0.05	versus	respective	fasted,	
**p <	0.01	versus	respective	fasted,	***p < 0.001 versus respective 
fasted,	****p < 0.0001 versus respective fasted. Data reported as 
means ± SEM
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GLP-1.	We	used	the	Milliplex	Map	Kit—Human	Metabolic	Hormone	
Magnetic	 Bead	 Panel	 (Cat	 #HMHEMAG-34K)	 with	 Luminex	
MAGPIX	 detection	 for	 determination	 of	 GLP-1	 (validated	 range	
2.7–2000	mg/ml)	and	GIP	(glucose-dependent	insulinotropic	pep-
tide)	 (validated	 range	 1.4–1000	 pg/ml),	 recovery	 for	 both	 was	
103% from serum.
4.4.2 | Micro- and macrovascular blood 
flow parameters
Two video recordings were obtained (baseline and postinterven-
tion)	by	 the	end	of	each	study.	Video	data	were	 then	exported	 to	
the	quantification	software	 (QLab,	Philips,	Andover,	MA,	USA)	 for	
analysis. Regions of interest were drawn avoiding areas of connec-
tive tissue and large vessels and copied into each file to ensure that 
regions were identical for each recording. The period immediately 
following	flash	(0.57	s)	was	used	to	calculate	the	background	acous-
tic	intensity	(AI),	an	arbitrary	unit,	attributable	to	rapidly	filing	larger	
non-exchange	vessels	and	tissue	echogenicity.	The	mean	AI	during	
this	was	calculated	and	subtracted	from	all	subsequent	values	during	
that	replenishment	period.	Then,	the	mean	AI	across	all	three	flash/
replenishment recording cycles was calculated after background cor-
rection and was curtailed at 24 s. The software automatically carries 
out	calculations	as	described	previously	(Sjøberg,	Rattigan,	Hiscock,	
Richter,	&	Kiens,	2011;	Wei	et	al.,	1998)	where	AI	versus	time	curves	
were fitted to the exponential function: y =	A[1	–e−β(t	−	Bt)],	where	t is 
time	in	seconds,	Bt	is	the	time	used	for	background	subtraction,	y	is	
the	AI	at	any	given	t,	A	is	the	plateau	AI	defined	as	MBV	in	ml	in	the	
ROI,	and	β is the flow rate constant (1itres s−1)	that	determines	the	
rate	of	rise	of	AI	and	corresponds	to	the	mean	blood	flow	velocity	or	
perfusion	rate	in	ml	per	sec.	of	all	vessels	in	the	ROI.	Then,	the	blood	
flow in ml per sec. can be defined as blood volume ⋅ blood flow ve-
locity (A ⋅ β)	(Weber	et	al.,	2006).	Leg	blood	flow	(LBF)	was	calculated	
using measurements obtained from ultrasound Doppler scan where 
LBF	is	determined	from	femoral	artery	dimensions	⋅ blood flow ve-
locity,	 from	 the	 average	 of	 at	 least	 3	measurements.	 Fold	 change	
from baseline was calculated as the difference between postpran-
dial blood flow and the postabsorptive blood flow relative to postab-
sorptive blood flow. Net incremental area under the response curve 
(AUC)	was	calculated	for	each	 individual	separately	and	presented	
as grouped analysis.
4.4.3 | Plasma AA concentration and 
Phe enrichment
For	 the	 measurement	 of	 AA	 concentration,	 internal	 standards	
were	added	to	plasma	samples,	before	the	addition	of	urease	solu-
tion	and	incubation	at	room	temperature	for	20	min.	Samples	were	
then	de-proteinised	with	ice-cold	ethanol	for	20	min	at	4°C,	before	
centrifugation	at	13,000	g. The supernatant containing plasma free 
AA	was	then	decanted	and	evaporated	at	90°C	under	N2.	Dried	AA	
were	solubilised	in	0.5	M	HCl	and	lipids	extracted	in	ethyl	acetate,	
before	being	evaporated	 to	dryness.	AA	were	derivatised	 through	
the	 addition	 of	 equal	 volumes	 of	 acetonitrile	 (ACN)	 and	 N-tert-
butyldimethylsilyl-N-methyltrifluoroacetamide	 (MTBSTFA)	 and	
heated	to	90°C	for	60	min	to	create	tert-butyldimethylsilyl	(t-BDMS)	
AA	esters.	Samples	were	allowed	to	cool	before	transfer	to	autosam-
pler	vials.	AA	concentrations	were	quantified	using	standard	curves	
of	known	concentrations	by	GC-MS,	as	per	our	standard	approach	
(Wilkinson	et	al.,	2018).	The	labelling	(atom	per	cent	excess	[APE])	
of	arterialised	and	venous	[13C6]phenylalanine was determined using 
GC-MS,	 by	measuring	 the	 ratio	of	 labelled	 to	unlabelled	Phe	 (m/z	
240–234).	 Concentrations	 for	 arterial	 plasma	 phenylalanine	 were	
determined	using	a	[15N]	phenylalanine	internal	standard	(m/z	235),	
with	reference	to	standard	curves	of	known	concentration	(Smith	&	
Rennie,	1996).
4.4.4 | Determination of muscle protein-bound and 
intracellular free phenylalanine enrichment
The muscle myofibrillar fraction was isolated as previously de-
scribed	(Atherton	et	al.,	2010;	Greenhaff	et	al.,	2008),	and	L-[ring-
13C6]-phenylalanine	 incorporation	 into	 myofibrillar	 protein	 was	
determined by gas chromatography combustion isotope ratio 
mass	 spectrometry	 (GC–C-IRMS,	 Delta-plus	 XP,	 Thermo,	 Hemel	
Hampstead,	UK).	Separation	was	achieved	on	a	25	m	·	0.25	mm	·	1.0	
μ-film	 DB	 1701	 capillary	 column	 (Agilent	 Technologies,	 West	
Lothian,	United	Kingdom).	Gas	chromatography	mass	spectrome-
try	(GC-MS,	Agilent-5977a,	California,	USA)	was	used	to	determine	
muscle	 intracellular	 L-[ring-13C6]-phenylalanine	 enrichment.	 The	
sarcoplasmic fraction containing the intramuscular free amino acid 
pool	was	precipitated,	and	the	supernatant	was	purified	by	cation-
exchange	chromatography,	using	Dowex	H+ resin and derivatised 
as	their	t-BDMS	derivatives	before	measurement	of	phenylalanine	
enrichment	 by	 GC-MS	 (Atherton	 et	 al.,	 2010;	 Greenhaff	 et	 al.,	
2008;	Mitchell	et	al.,	2015).
4.4.5 | Calculation of fractional synthesis rates
FSR	was	calculated	via	measurement	of	the	increase	in	L-[ring-13C6]-
phenylalanine enrichment into myofibrillar protein between two 
consecutive	biopsies.	The	calculations	used	the	standard	precursor-
product	equation:
where ΔEm	 is	 the	 change	 in	 labelling	 of	muscle	 bound	 L-[ring-
13C6]-
phenylalanine	between	2	biopsy	samples,	Ep	is	the	mean	L-[ring-
13C6] 
free	 phenylalanine	 precursor	 enrichment	 in	 the	 intramuscular	 pool,	
and t is the time in hours between biopsies.
FSR [expressed as % hr−1] = (ΔEm∕Ep×1∕t)×100
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4.4.6 | Phenylalanine kinetics across the leg
Phenylalanine	 delivery	 to	 the	 leg	 was	 calculated	 as:	 LBF	 × CA. 
Phenylalanine	 release	 from	 the	 leg	 was	 calculated	 as:	 LBF	 × CV. 
Muscle	protein	net	balance	(NB)	was	calculated	as	(CA	−	CV)	×	LBF.	
The	rate	of	appearance,	that	is	MPB,	was	calculated	from	the	dilu-
tion	of	tracer	across	the	leg,	as	(EA/EV	−	1)	×	LBF	× CA; the rate of dis-
appearance	of	phenylalanine,	that	is	MPS,	was	calculated	indirectly	
as	the	sum	of	MPB	+	muscle	protein	net	balance	(NB)	where	NB	is	
(CA	−	CV)	×	LBF,	where	CA and CV are concentration of phenylalanine 
in	the	femoral	artery	and	vein,	respectively,	and	EA and EV are phe-
nylalanine	enrichment	 in	 the	 femoral	artery	and	vein,	 respectively	
(Bennet,	Connacher,	Scrimgeour,	Jung,	&	Rennie,	1990).
4.4.7 | Immunoblotting analysis of 
signalling proteins
Phosphorylated	 protein	 concentrations	were	 determined	by	Western	
blotting	(Cell	Signalling	Technology,	London,	UK)	for	eukaryotic	elonga-
tion	factor	2	 (eEF2)	Thr56—Catalogue	No	2331;	p70	ribosomal	S6	ki-
nase	 (p70	S6K1)	Thr389—Catalogue	No	9234;	AKT	Ser473—Catalogue	
No	4060;	mammalian	target	of	rapamycin	 (mTOR)	Ser2448—Catalogue	
No	 5536;	 eukaryotic	 initiation	 factor	 4E	 binding	 protein	 1	 (4E-BP1)	
Thr37/46—Catalogue	No	2855;	and	tuberous	sclerosis	complex	2	(TSC2)	
Thr1462—Catalogue	No	3611.	Proteins	were	extracted	from	~20 mg of 
crudely	minced	muscle	in	ice-cold	buffer	containing	50	mmol	L−1	Tris-HCl,	
1	mmol	L−1	EDTA,	1	mmol	L−1	EGTA,	10	mmol	L−1 β-glycerophosphate,	
0.5	 mmol	 L−1 sodium orthovanadate and complete protease inhibi-
tor	 cocktail	 (Roche,	West	 Sussex,	 United	 Kingdom).	 Protein	 concen-
trations were determined using a NanoDrop 2000 (Thermo Fisher 
Scientific).	Twenty	micrograms	of	each	protein	sample	was	loaded	onto	
12%	sodium	dodecyl	sulphate–polyacrylamide	gel	electrophoresis	gel	
(Criterion	 XT	 Bis-Tris;	 Bio-Rad,	 Hemel	 Hempstead,	 United	 Kingdom)	
for	electrophoresis	at	200	V	for	60	min	and	electroblotted	to	polyvi-
nylidene	difluoride	membranes	 (Bio-Rad).	After	 incubation	for	1	hr	at	
room	temperature	with	5%	milk	in	TBS-T	(Tris-buffered	saline	and	0.1%	
Tween-20),	membranes	were	 incubated	 overnight	with	 primary	 anti-
body	against	the	aforementioned	targets	at	4°C	(New	England	Biolabs).	
Membranes were then washed for 3 ×	5	min	with	TBS-T	and	incubated	
for	1	hr	at	room	temperature	with	1:2000	horseradish	peroxidase-con-
jugated	anti-rabbit	secondary	antibody	 (New	England	Biolabs),	before	
further	washing	with	 TBS-T	 and	 incubation	 for	 5	min	with	 chemilu-
minescence	 reagents	 (Immobilon	 Western	 Chemiluminescent	 HRP	
Substrate;	Millipore).	Blots	were	imaged	and	quantified	with	the	use	of	
the	ChemiDoc	XRS	system	(Bio-Rad).	Normalisation	of	proteins	of	inter-
est was performed against Coomassie blue staining.
4.4.8 | Gene expression of GLP-1 receptor (GLP-1r)
Total	RNA	from	human	skeletal	muscle	(CD56+)	cells,	human	skel-
etal	muscle	tissue,	human	adipose	tissue	and	human	kidney	cells	
(n =	 6–8	per	 cell	 type)	was	 extracted	 using	TRI	 reagent	 (Sigma-
Aldrich,	 UK),	 according	 to	 the	manufacturer's	 instructions.	 RNA	
was resuspended in 20 μl	RNase-free	water	and	quantified	using	a	
NanoDrop™	2000	(Thermo	Fisher	Scientific).	Reverse	transcription	
was	performed	with	500	ng	RNA	using	the	High-Capacity	cDNA	
Synthesis	Kit	(Applied	Biosystems,	Thermo	Fisher	Scientific).	1	µl 
of	cDNA	(in	duplicate)	was	added	into	384-well	plates	with	primers	
specific to GLP1R	 (5′–3′;	 forward:	GACGCTCAAGAATCCTCTGG;	
reverse:	TCAAGAGACAGCGTGTGGTC)	 and	SYBR	Select	Master	
Mix	 (Applied	 Biosystems,	 Thermo	 Fisher	 Scientific)	 in	 a	 total	
volume of 7 µl.	Plates	were	 run	on	a	ViiA™	7	 real-time	PCR	sys-
tem	 (Thermo	 Fisher	 Scientific).	 The	 gene	 RPL13A was used for 
normalisation.
4.5 | Statistical analysis
The	sample	size	was	prospectively	determined	based	on	previous	local	
studies to detect difference in muscle metabolism. For repeated meas-
ures	of	MPS	in	the	same	sample,	the	coefficient	of	variation	(CV)	is	~3.8%.	
The	population	CVs	are	~10-12%	for	young	and	older	men.	For	MPB,	
with	a	population	CV	of	15%	(based	on	previous	 laboratory	data)	and	
CV	of	 laboratory	techniques	also	of	15%	(propagated	error	~21%),	we	
were	able	to	detect	(with	80%	confidence	at	the	5%	significance	level)	
differences	in	rates	of	MPB	after	feeding	of	±21% (i.e. 1 SD).	Given	these	
parameters,	 the	 smallest	 number	 of	 subjects	 needed	 to	 detect	 (with	
80%	confidence,	5%	significance	level)	a	cross-sectional	difference	be-
tween	groups,	or	a	one-way	difference	on	a	paired	basis,	of	20%	was	8.	
Analysis	was	conducted	using	Prism	7	(GraphPad,	San	Diego,	CA).	Data	
are presented as mean ± SEM. Normality of distribution was tested using 
D’Agostino	and	Pearson	Omnibus	normality	tests.	Comparison	between	
experiments	 and	 values	 was	 made	 via	 repeated-measures	 two-way	
ANOVA	or	Student's	 t	 test	 as	 appropriate,	with	Bonferroni	 correction	
for multiple comparisons. Data were accepted as significant if p < 0.05.
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